We have a total production capacity of eight billion capsules per year

HC Jain, Chairman and Managing Director, Erawat Pharma, talks on the current market trends in capsules, his company’s offerings for the pharma sector, impact of COVID-19 on his company and the sector, in an interview with Express Pharma

- HC Jain

What are the dominant trends in empty hard gelatin capsules, in India and globally?

As per the various research reports published recently the global empty gelatin capsule market was valued at $1841.5 million in 2017. It is showing a steady CAGR of 9.1 per cent from 2018 and is expected to reach a valuation of $3707.5 million by 2025.

India had a production a capacity of around 102 billion capsules in quantity in 2017-18. Roughly 40 per cent of this capacity is exported from India.

Tell us about the products you offer to India as well as international markets?

We have a total production capacity of eight billion capsules per year; which comes from Erawat Pharma and its group companies together. We are supplying our Indian and overseas clients with a very wide range of sizes to cater to almost all types of capsule dosages requirements. We are manufacturing capsules in size 00, 0el, 0, 1, 2, 3, 4, and 5. 00 being the biggest and size 5 being the smallest one. Depending on the customers’ requirements, these are then manufactured in various varieties suitable for dry powder inhalers, capsules filled with liquids, aesthetically attractive capsules, preservative-free capsules, etc., to name a few.

Then we have HPMC (popularly known as veg) capsules also in all sizes and varieties for specific customer requirements.

Your company has an established presence in the Indian market for 23 years, how do you plan to expand your international business?